Abiopharma

New Form 8-K - PAVmed Inc. Filed: 2025-08-14 AccNo: 0001641172-25-023729 Size: 310 KB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

New Form 8-K - Cocrystal Pharma, Inc. Filed: 2025-08-14 AccNo: 0001641172-25-023727 Size: 358 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

New Form 8-K - Enveric Biosciences, Inc. Filed: 2025-08-14 AccNo: 0001641172-25-023724 Size: 267 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

New Form 10-Q - BRAINSTORM CELL THERAPEUTICS INC. Filed: 2025-08-14 AccNo: 0001410578-25-001782 Size: 3 MB

MeiraGTx Reports Second Quarter 2025 Financial and Operational Results

New Form SCHEDULE 13G/A - ROCKET PHARMACEUTICALS, INC. Filed: 2025-08-14 AccNo: 0001641172-25-023726 Size: 11 KB

New Form 8-K - Applied Therapeutics, Inc. Filed: 2025-08-14 AccNo: 0000950170-25-108441 Size: 145 KB Item 8.01: Other Events

New Form SCHEDULE 13G/A - Akero Therapeutics, Inc. Filed: 2025-08-14 AccNo: 0001415889-25-021700 Size: 10 KB

New Form 10-Q - PALVELLA THERAPEUTICS, INC. Filed: 2025-08-14 AccNo: 0000950170-25-108438 Size: 7 MB

bioAffinity Technologies Reports Second Quarter 2025 Results

PAVmed Provides Business Update and Reports Second Quarter 2025 Financial Results

Orchestra BioMed Announces Publication of AVIM Therapy Clinical Data in JACC: Advances Demonstrating Potential to Improve Cardiac Function in Patients with Hypertension and Diastolic Dysfunction

Cocrystal Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

New Form 8-K - GALECTIN THERAPEUTICS INC Filed: 2025-08-14 AccNo: 0001140361-25-031041 Size: 868 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

ZyVersa Therapeutics Highlights Data Demonstrating a Critical Need for Therapies to Address Kidney Lipotoxicity to Alleviate Diabetic Kidney Disease (DKD) and Its Progression